SOR-C13 TFA, an extraordinary and highly specialized inhibitor deployed within the biomedical sphere for the purpose of combating cancer, embodies immense potency. Notably designed to single out sorafenib-resistant cells, it amplifies the efficacy of the widely employed sorafenib drug, primarily acclaimed for its profound impact against advanced renal cell carcinoma and liver malignancies.
CAT# | R2011 |
M.F/Formula | C74H117F3N20O21 |
M.W/Mr. | 1679.84 |
Appearance | Solid |
* Please kindly note that our products and services can only be used to support research purposes (Not for clinical use).
Creative Peptides has accumulated a huge library of peptide knowledge including frontier peptide articles, application of peptides, useful tools, and more!
Background Aclerastide, one angiotensin receptor agonist, is the active ingredient of DSC127 and its general structure is sho ...
DAPTA (D-[Ala]-Ser-Thr-Thr-Thr-Asn-Tyr-Thr-amide), D-Ala-Peptide T amide, is one of analogue of peptide T, which ...
Acid-sensitive ion channels (ASICs) are a class of proton-gated ion channels belonging to the Degenerin/Epitheli ...
GR 64349 is a selective and potent NK2 agonist (EC50 = 3.7 nM in rat colon) with activity comparable to that of ...
Muramyl dipeptide (MDP) is the smallest structural unit with immune activity in the skeleton of bacille calmette ...